Identifying the Key Drivers of Biosimilar Uptake in Paris University Hospitals Using a Principal Component Analysis

Speaker(s)

Boudjenah Y1, Tano M2, Siorat V3, Parent de Curzon O1, Degrassat Theas A4, Paubel P5
1General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), PARIS, France, 2Faculty of Pharmacy, Paris University, Paris, France, 3General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 4General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP) ; Law and Health Economics Department, Faculty of Pharmacy & Health Law Institute (INSERM UMR S1145) University of Paris Cité, Paris, France, 5General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP) ; Law and Health Economics Department, Faculty of Pharmacy & Health Law Institute (INSERM UMR S1145) University of Paris, Paris, France

Presentation Documents

OBJECTIVES: Biosimilar drugs have been on the European market for almost ten years and represent the opportunity to generate cost savings for the healthcare system. Furthermore, biosimilar use is supported by recent French national incentives for outpatient drugs prescribed by hospital physicians. The financial impact and the market penetration of biosimilar (MPBS) differ substantially between products, pathologies, and physician prescriptions. The study objective is to identify the drivers of biosimilar uptake in the 39 Paris University Hospitals (AP-HP).

METHODS: A Principal Component Analysis (PCA) on R software modelled seven key variables that explain the MPBS, linked to the competitive environment and the drug: administration route, overall quantity per year, and drug delivery circuit. These variables were analysed for seven drugs for which biosimilars are in competition with the brand name drug (set by international non-proprietary name INN): infliximab, rituximab, trastuzumab, bevacizumab, adalimumab, etanercept and pegfilgrastim. For each product, the MPBS was annually calculated at AP-HP since the first competition to June 2022.

RESULTS: In average, MPBS reached 82%. The dimensions 1 and 2 of the PCA explained 77% of the MPBS variance. Six variables are positively correlated to MPBS: the overall quantity used in AP-HP, the tender’s long standing, the drug reconstitution in hospital pharmacy rather than in units care, the pathology chronicity, the presence of an only one administration route (intravenous route), and the number of biopharmaceuticals per INN. Otherwise, the drug’s availability through retail pharmacies contributes negatively to the MPBS.

CONCLUSIONS: Our results suggest that MPBS is related to AP-HP drug policy for biopharmaceuticals mainly used at hospital, which represent a significant financial issue (high volume consumed, long standing tenders). Future researches should be conducted in each AP-HP facility to confirm the findings and should broaden the analysis to other hospitals.

Code

HPR14

Topic

Economic Evaluation, Health Policy & Regulatory

Topic Subcategory

Public Spending & National Health Expenditures, Reimbursement & Access Policy

Disease

STA: Biologics & Biosimilars